Others risk factors involved with HAI development among COVID-19 patients admitted to ICU in our study were those prescribed anticoagulants, antithrombotic, antivirals and IL-6 inhibitors including tocilizumab, with tocilizumab typically prescribed to severe or critical patients. The gene discussed is IL6; the disease is COVID-19.